Literature DB >> 17326147

Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.

Luca Di Tommaso1, Giada Franchi, Young Nyun Park, Barbara Fiamengo, Annarita Destro, Emanuela Morenghi, Marco Montorsi, Guido Torzilli, Maurizio Tommasini, Luigi Terracciano, Luigi Tornillo, Raffaella Vecchione, Massimo Roncalli.   

Abstract

UNLABELLED: Hepatocellular nodules in cirrhosis include regenerative (large regenerative, LRN) and dysplastic (low and high grade, LGDN and HGDN) nodules, early and grade 1 HCC (eHCC-G1), and overt HCC. The differential diagnosis may be particularly difficult when lesions such as HGDN and eHCC-G1 are involved. We investigated the diagnostic yield of a panel of 3 putative markers of hepatocellular malignancy such as HSP70, glypican 3 (GPC3), and glutamine synthetase (GS). We selected 52 surgically removed nonmalignant nodules (15 LRNs, 15 LGDNs, 22 HGDNs) and 53 HCCs (10 early, 22 grade 1, and 21 grade 2-3) and immunostained them for HSP70, GPC3, and GS. The sensitivity and specificity of the individual markers for the detection of eHCC-G1 were 59% and 86% for GS, 69% and 91% for GPC3, and 78% and 95% for HSP70. We identified 2 main phenotypes: (1) all negative, seen in 100% LRN and LGDN, 73% HGDN and 3% eHCC-G1; (2) all positive, a feature detected in less than half the eHCC-G1. Using a 3-marker panel, when at least 2 of them, regardless which, were positive, the sensitivity and specificity for the detection of eHCC-G1 were respectively 72% and 100%; the most sensitive combination was HSP70+/GPC3+ (59%) when a 2-marker panel was used.
CONCLUSION: The adopted panel of 3 markers is very helpful in distinguishing eHCC-G1 from dysplastic nodules arising in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17326147     DOI: 10.1002/hep.21531

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  105 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

3.  Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III: Characterization of DDX3X as a target of S-adenosylmethionine.

Authors:  Paul C Schröder; Joaquín Fernández-Irigoyen; Emilie Bigaud; Antonio Serna; Rubén Renández-Alcoceba; Shelly C Lu; José M Mato; Jesús Prieto; Fernando J Corrales
Journal:  J Proteomics       Date:  2012-01-16       Impact factor: 4.044

4.  Early HCC: diagnosis and molecular markers.

Authors:  Michiie Sakamoto
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

5.  Early hepatocellular carcinoma: definition and diagnosis.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

6.  TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.

Authors:  Sayaka Inokuchi-Shimizu; Eek Joong Park; Yoon Seok Roh; Ling Yang; Bi Zhang; Jingyi Song; Shuang Liang; Michael Pimienta; Koji Taniguchi; Xuefeng Wu; Kinji Asahina; William Lagakos; Mason R Mackey; Shizuo Akira; Mark H Ellisman; Dorothy D Sears; Jerrold M Olefsky; Michael Karin; David A Brenner; Ekihiro Seki
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

7.  A case of progressing focal nodular hyperplasia and its molecular expression pattern.

Authors:  Kazuto Tajiri; Koichi Tsuneyama; Kengo Kawai; Yoshinari Atarashi; Masami Minemura; Shigeaki Sawada; Kazuhiro Tsukada; Johji Imura; Toshiro Sugiyama
Journal:  Clin J Gastroenterol       Date:  2014-04-12

8.  Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence.

Authors:  Frederique Caillot; Celine Derambure; Paulette Bioulac-Sage; Arnaud Francois; Michel Scotte; Odile Goria; Martine Hiron; Maryvonne Daveau; Jean Philippe Salier
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

9.  [Highly differentiated liver tumors: recent developments and their diagnostic application].

Authors:  P Schirmacher; T Longerich
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

10.  Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours.

Authors:  Renee G H M van Sprundel; Ted S G A M van den Ingh; Valeer J Desmet; Azeam Katoonizadeh; Louis C Penning; Jan Rothuizen; Tania Roskams; Bart Spee
Journal:  Comp Hepatol       Date:  2010-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.